AgingResearch.NewsJoin free

Resolve Therapeutics

CompanyUnited States

Resolve Therapeutics develops one asset, in phase 2 (RSLV-132 in Sjögren disease). Mostly protein or enzyme acting on inflammation; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • RSLV-132

    RNase fusion protein degrades extracellular RNA to reduce RNA-driven inflammatory activation.

    Phase 2, Protein or enzyme, Inflammation, Sjögren disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence